Literature DB >> 23440420

KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis.

Isabel Wong-Baeza1, Anna Ridley, Jackie Shaw, Hiroko Hatano, Oliwia Rysnik, Kirsty McHugh, Christopher Piper, Simon Brackenbridge, Ricardo Fernandes, Anthoni Chan, Paul Bowness, Simon Kollnberger.   

Abstract

The human leukocyte Ag HLA-B27 (B27) is strongly associated with the spondyloarthritides. B27 can be expressed at the cell surface of APC as both classical β2-microglobulin-associated B27 and B27 free H chain forms (FHC), including disulfide-bonded H chain homodimers (termed B27(2)). B27 FHC forms, but not classical B27, bind to KIR3DL2. HLA-A3, which is not associated with spondyloarthritis (SpA), is also a ligand for KIR3DL2. In this study, we show that B27(2) and B27 FHC bind more strongly to KIR3DL2 than other HLA-class I, including HLA-A3. B27(2) tetramers bound KIR3DL2-transfected cells more strongly than HLA-A3. KIR3DL2Fc bound to HLA-B27-transfected cells more strongly than to cells transfected with other HLA-class I. KIR3DL2Fc pulled down multimeric, dimeric, and monomeric FHC from HLA-B27-expressing cell lines. Binding to B27(2) and B27 FHC stimulated greater KIR3DL2 phosphorylation than HLA-A3. B27(2) and B27 FHC stimulated KIR3DL2CD3ε-transduced T cell IL-2 production to a greater extent than control HLA-class I. KIR3DL2 binding to B27 inhibited NK IFN-γ secretion and promoted greater survival of KIR3DL2(+) CD4 T and NK cells than binding to other HLA-class I. KIR3DL2(+) T cells from B27(+) SpA patients proliferated more in response to Ag presented by syngeneic APC than the same T cell subset from healthy and disease controls. Our results suggest that expansion of KIR3DL2-expressing leukocytes observed in B27(+) SpA may be explained by the stronger interaction of KIR3DL2 with B27 FHC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23440420      PMCID: PMC3736094          DOI: 10.4049/jimmunol.1202926

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

Review 1.  HLA-B27 and the pathogenesis of spondyloarthropathies.

Authors:  José A López de Castro
Journal:  Immunol Lett       Date:  2006-11-16       Impact factor: 3.685

2.  Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis.

Authors:  A T Chan; S D Kollnberger; L R Wedderburn; P Bowness
Journal:  Arthritis Rheum       Date:  2005-11

3.  Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705.

Authors:  Guillame B E Stewart-Jones; Kati di Gleria; Simon Kollnberger; Andrew J McMichael; E Yvonne Jones; Paul Bowness
Journal:  Eur J Immunol       Date:  2005-02       Impact factor: 5.532

4.  Free HLA class I heavy chain-carrying monocytes--a potential role in the pathogenesis of spondyloarthropathies.

Authors:  Wen Chan Tsai; Chung Jen Chen; Jeng Hsien Yen; Tsang Teng Ou; Jih Jin Tsai; Chiang Shin Liu; Hong Wen Liu
Journal:  J Rheumatol       Date:  2002-05       Impact factor: 4.666

5.  HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading.

Authors:  C A Peh; S R Burrows; M Barnden; R Khanna; P Cresswell; D J Moss; J McCluskey
Journal:  Immunity       Date:  1998-05       Impact factor: 31.745

6.  Relationships between mandibular cortical bone measures and biochemical markers of bone turnover in elderly Japanese men and women.

Authors:  Ichizo Morita; Haruo Nakagaki; Akira Taguchi; Kazuo Kato; Taeko Murakami; Shinji Tsuboi; Junko Hayashizaki; Koji Inagaki; Toshihide Noguchi
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-07-01

7.  Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.

Authors:  Aline Martayan; Leonardo Sibilio; Elisa Tremante; Elisa Lo Monaco; Arend Mulder; Doriana Fruci; Agata Cova; Licia Rivoltini; Patrizio Giacomini
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

8.  Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype.

Authors:  Cyril Fauriat; Sandra Andersson; Andreas T Björklund; Mattias Carlsten; Marie Schaffer; Niklas K Björkström; Bettina C Baumann; Jakob Michaëlsson; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific.

Authors:  Pokrath Hansasuta; Tao Dong; Hathairat Thananchai; Michael Weekes; Christian Willberg; Hatice Aldemir; Sarah Rowland-Jones; Veronique M Braud
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

10.  Consistent patterns of expression of HLA class I free heavy chains in healthy individuals and raised expression in spondyloarthropathy patients point to physiological and pathological roles.

Authors:  T Raine; D Brown; P Bowness; J S Hill Gaston; A Moffett; J Trowsdale; R L Allen
Journal:  Rheumatology (Oxford)       Date:  2006-08-27       Impact factor: 7.580

View more
  38 in total

Review 1.  Dendritic cells in the pathogenesis of ankylosing spondylitis and axial spondyloarthritis.

Authors:  Gleb Slobodin; Itzhak Rosner; Aharon Kessel
Journal:  Clin Rheumatol       Date:  2018-12-05       Impact factor: 2.980

Review 2.  Polymorphism of HLA-B27: 105 subtypes currently known.

Authors:  Muhammad Asim Khan
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

Review 3.  KIR and HLA under pressure: evidences of coevolution across worldwide populations.

Authors:  Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-06-23       Impact factor: 4.132

4.  The D0 Ig-like domain plays a central role in the stronger binding of KIR3DL2 to B27 free H chain dimers.

Authors:  Hiroko Hatano; Jacqueline Shaw; Kaitlin Marquardt; Zhiyong Zhang; Laurent Gauthier; Stephanie Chanteux; Benjamin Rossi; Demin Li; Julie Mitchell; Simon Kollnberger
Journal:  J Immunol       Date:  2015-01-12       Impact factor: 5.422

5.  α3-Deletion Isoform of HLA-A11 Modulates Cytotoxicity of NK Cells: Correlations with HIV-1 Infection of Cells.

Authors:  Xi-He Zhang; Xiao-Dong Lian; Zheng-Xi Dai; Hong-Yi Zheng; Xin Chen; Yong-Tang Zheng
Journal:  J Immunol       Date:  2017-08-07       Impact factor: 5.422

6.  Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet's disease.

Authors:  B Erer; M Takeuchi; D Ustek; I Tugal-Tutkun; E Seyahi; Y Özyazgan; J Duymaz-Tozkir; A Gül; D L Kastner; E F Remmers; M J Ombrello
Journal:  Genes Immun       Date:  2016-10-06       Impact factor: 2.676

Review 7.  Juvenile Spondyloarthritis: What More Do We Know About HLA-B27, Enthesitis, and New Bone Formation?

Authors:  Shi Huan Tay; Joo Guan Yeo; Jing Yao Leong; Salvatore Albani; Thaschawee Arkachaisri
Journal:  Front Med (Lausanne)       Date:  2021-05-20

8.  Allelic association with ankylosing spondylitis fails to correlate with human leukocyte antigen B27 homodimer formation.

Authors:  Terry C C Lim Kam Sian; Saranjah Indumathy; Hanim Halim; Anja Greule; Max J Cryle; Paul Bowness; Jamie Rossjohn; Stephanie Gras; Anthony W Purcell; Ralf B Schittenhelm
Journal:  J Biol Chem       Date:  2019-11-18       Impact factor: 5.157

9.  An HLA-B27 Homodimer Specific Antibody Recognizes a Discontinuous Mixed-Disulfide Epitope as Identified by Affinity-Mass Spectrometry.

Authors:  Marius-Ionuţ Iuraşcu; Osiris Marroquin Belaunzanar; Claudia Cozma; Ulf Petrausch; Christoph Renner; Michael Przybylski
Journal:  J Am Soc Mass Spectrom       Date:  2016-04-11       Impact factor: 3.109

10.  Allele-specific Alterations in the Peptidome Underlie the Joint Association of HLA-A*29:02 and Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) with Birdshot Chorioretinopathy.

Authors:  Alejandro Sanz-Bravo; Adrian Martín-Esteban; Jonas J W Kuiper; Marina García-Peydró; Eilon Barnea; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2018-05-16       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.